drugset / Trial / NCT00798525
Argatroban Versus Lepirudin in Critically Ill Patients
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to test the hypotheses that argatroban significantly increases efficacy and safety of renal replacement therapy measured as life time of haemodialysis filters as compared to lepirudin
Timeline
- Start
- 2009-01
- Primary completion
- 2012-03
- Completion
- 2012-03
Publications
- Tsujimoto H, Tsujimoto Y, Nakata Y, Fujii T, Takahashi S, Akazawa M, Kataoka Y. Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy. Cochrane Database Syst Rev. 2020 Dec 14;12(12):CD012467. doi: 10.1002/14651858.CD012467.pub3.
- Beiderlinden M, Werner P, Bahlmann A, Kemper J, Brezina T, Schafer M, Gorlinger K, Seidel H, Kienbaum P, Treschan TA. Monitoring of argatroban and lepirudin anticoagulation in critically ill patients by conventional laboratory parameters and rotational thromboelastometry - a prospectively controlled randomized double-blind clinical trial. BMC Anesthesiol. 2018 Feb 9;18(1):18. doi: 10.1186/s12871-018-0475-y.
- Treschan TA, Schaefer MS, Geib J, Bahlmann A, Brezina T, Werner P, Golla E, Greinacher A, Pannen B, Kindgen-Milles D, Kienbaum P, Beiderlinden M. Argatroban versus Lepirudin in critically ill patients (ALicia): a randomized controlled trial. Crit Care. 2014 Oct 25;18(5):588. doi: 10.1186/s13054-014-0588-8.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Argatroban | Small molecule | 0.25 ug/kg | — |
| Comparator | Argatroban | Small molecule | 0.5 ug/kg | — |
| Comparator | Lepirudin | Protein / enzyme biologic | 5 ug/kg | — |
| Comparator | Lepirudin | Protein / enzyme biologic | 10 ug/kg | — |
| Comparator | Lepirudin | Protein / enzyme biologic | 50 ug/kg | — |